| Psoriasis vulgaris
Duobrii vs Wynzora
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Duobrii vs Wynzora with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWynzora has a higher rate of injection site reactions vs Duobrii based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wynzora but not Duobrii, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Duobrii
Wynzora
At A Glance
Topical
Once daily
Corticosteroid/retinoid combination
Topical
Daily
Vitamin D3 analog + corticosteroid
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Psoriasis vulgaris Apply to affected areas once daily for up to 8 weeks; do not use more than 100 g per week; discontinue when control is achieved.
Contraindications
- Pregnancy
—
Adverse Reactions
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Most common (>=1%) Upper respiratory infection, headache, application site irritation
Postmarketing Atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure
Pharmacology
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
WYNZORA Cream combines calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; the exact mechanisms of their actions in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Duobrii
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Wynzora
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Duobrii
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Wynzora
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Duobrii
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Wynzora
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Duobrii.
No savings programs available for Wynzora.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DuobriiView full Duobrii profile
WynzoraView full Wynzora profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.